Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.47
Equity-to-Asset	0.57
Debt-to-Equity	0.39
Debt-to-EBITDA	-3.72
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.95	Distress Grey Safe
Beneish M-Score	-2.73	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	9.2
	3-Year EPS without NRI Growth Rate	-42.2
	3-Year FCF Growth Rate	-33.3
	3-Year Book Growth Rate	4
	Future 3-5Y EPS without NRI Growth Rate	22.9
	Future 3-5Y Total Revenue Growth Rate	11.4

Momentum Rank

5/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	63.38
	9-Day RSI	51.6
	14-Day RSI	47.8
	6-1 Month Momentum %	15.07
	12-1 Month Momentum %	-38.78

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.66
	Quick Ratio	1.29
	Cash Ratio	0.67
	Days Inventory	123.38
	Days Sales Outstanding	56.74
	Days Payable	52.46

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-2.9
	Shareholder Yield %	0.52

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	60.95
	Operating Margin %	-5.02
	Net Margin %	-25.76
	FCF Margin %	6.23
	ROE %	-18.42
	ROA %	-10.34
	ROIC %	-2.52
	ROC (Joel Greenblatt) %	-56.94
	ROCE %	-11.38
	Years of Profitability over Past 10-Year	8

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	Forward PE Ratio	126.58
	PE Ratio without NRI	153.57
	Shiller PE Ratio	182.97
	PS Ratio	4.36
	PB Ratio	3.44
	Price-to-Tangible-Book	93.69
	Price-to-Free-Cash-Flow	69.69
	Price-to-Operating-Cash-Flow	41.11
	EV-to-EBIT	-19.89
	EV-to-Forward-EBIT	110.51
	EV-to-EBITDA	-34.01
	EV-to-Forward-EBITDA	50.49
	EV-to-Revenue	4.59
	EV-to-Forward-Revenue	4.65
	EV-to-FCF	74.53
	Price-to-Projected-FCF	1.93
	Price-to-Median-PS-Value	0.33
	Price-to-Graham-Number	24.96
	Earnings Yield (Greenblatt) %	-5.03
	FCF Yield %	1.44
	Forward Rate of Return (Yacktman) %	-0.98

GF Value: €195.5

STU:ILU

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with ILU. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.